natgillin/translations-raw huggingface dataset:
It must not be used in patients who have a disease that is causing bleeding, such as stomach ulcer or bleeding in the brain, or in patients with mastocytosis (high blood levels of certain white blood cells called mast cells).
Prav tako se ne sme uporabljati pri bolnikih, ki imajo bolezen, ki povzroča krvavitve, kot je na primer razjeda želodca ali krvavitev v možganih, in pri bolnikih z mastocitozo (visokimi ravnmi določenih belih krvnih celic, imenovanih mastociti, v krvi).
Clopidogrel/Acetylsalicylic acid Teva is available as tablets containing 75 mg clopidogrel, either with 75 mg or 100 mg acetylsalicylic acid.
Zdravilo Klopidogrel/acetilsalicilna kislina Teva je na voljo v obliki tablet, ki vsebujejo 75 mg klopidogrela v kombinaciji z bodisi 75 mg ali 100 mg acetilsalicilne kisline.
The most common side effects with Clopidogrel/Acetylsalicylic acid Teva (which may affect up to 1 in 10 people) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), diarrhoea, abdominal pain (stomach ache), dyspepsia (heartburn), bruising, and bleeding where the skin is punctured.
Najpogostejši neželeni učinki zdravila Klopidogrel/acetilsalicilna kislina Teva (ki lahko prizadenejo največ 1 osebo od 10) so hematom (nabiranje krvi pod kožo), epistaksa (krvavitve iz nosu), gastrointestinalna krvavitev (krvavitev v želodcu ali črevesju), driska, bolečina v trebuhu (bolečina v želodcu), dispepsija (zgaga), podplutbe in krvavitev na mestu predrtja kože.
For more information about treatment with Clopidogrel/Acetylsalicylic acid Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Klopidogrel/acetilsalicilna kislina Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What measures are being taken to ensure the safe and effective use of Clopidogrel/Acetylsalicylic acid Teva?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Klopidogrel/acetilsalicilna kislina Teva?
Acetylsalicylic acid stops the platelets sticking together by blocking an enzyme called prostaglandin cyclo-oxygenase.
Acetilsalicilna kislina prepreči sprijetje trombocitov tako, da zavira encim, imenovan prostaglandinska ciklooksigenaza.
The medicine is taken as a single tablet daily in place of the clopidogrel and acetylsalicylic acid tablets that the patient has already been taking separately.
Zdravilo se jemlje z eno tableto na dan, ki jo bolnik vzame namesto tablet klopidogrela in acetilsalicilne kisline, ki ju je prej jemal ločeno.
Clopidogrel/Acetylsalicylic acid Teva must not be used in people who are hypersensitive (allergic) to clopidogrel, non-steroidal anti-inflammatory drugs (NSAIDs, used to relieve pain and inflammation) such as acetylsalicylic acid, or any of the other ingredients in Clopidogrel/Acetylsalicylic acid Teva.
Zdravilo Klopidogrel/acetilsalicilna kislina Teva se ne sme uporabljati pri osebah, ki so preobčutljive za (alergične na) klopidogrel, nesteroidna protivnetna zdravila (NSAID, tj. zdravila, ki se uporabljajo za lajšanje bolečine in vnetja), kot je acetilsalicilna kislina, ali katero koli drugo sestavino zdravila Klopidogrel/acetilsalicilna kislina Teva.
This reduces the production of a substance called thromboxane, which normally helps clots to form by binding platelets together.
Zaradi tega se zmanjša tvorba snovi, imenovane tromboksan, ki običajno veže trombocite skupaj in tako prispeva k nastanku strdkov.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Clopidogrel/Acetylsalicylic acid Teva, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Klopidogrel/acetilsalicilna kislina Teva in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For practical information about using Clopidogrel/Acetylsalicylic acid Teva, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Klopidogrel/acetilsalicilna kislina Teva naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Both active substances in Clopidogrel/Acetylsalicylic acid Teva, clopidogrel and acetylsalicylic acid, are antiplatelet medicines.
Obe zdravilni učinkovini v zdravilu Klopidogrel/acetilsalicilna kislina Teva, klopidogrel in acetilsalicilna kislina, sta antiagregacijski zdravili.
A risk management plan has been developed to ensure that Clopidogrel/Acetylsalicylic acid Teva is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Klopidogrel/acetilsalicilna kislina Teva je bil pripravljen načrt obvladovanja tveganj.
It must not be used in patients who have severely reduced liver or kidney function, or who have a medical condition that includes a combination of asthma, rhinitis (stuffy and runny nose) and nasal polyps (growths in the lining of the nose).
Ne sme se uporabljati tudi pri bolnikih, ki imajo močno zmanjšano delovanje jeter ali ledvic ali obolenje, ki je kombinacija astme, rinitisa (zamašen nos in izcedek iz nosu) ter nosnih polipov (izrastki na nosni sluznici).
For the full list of all side effects reported with Clopidogrel/Acetylsalicylic acid Teva, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Klopidogrel/acetilsalicilna kislina Teva, glejte navodilo za uporabo.
Other information about Clopidogrel/Acetylsalicylic acid Teva
Druge informacije o zdravilu Klopidogrel/acetilsalicilna kislina Teva
What are the risks associated with Clopidogrel/Acetylsalicylic acid Teva?
Kakšna tveganja so povezana z zdravilom Klopidogrel/acetilsalicilna kislina Teva?
Clopidogrel/Acetylsalicylic acid Teva is a blood thinning medicine that contains two active substances, clopidogrel and acetylsalicylic acid.
Klopidogrel/acetilsalicilna kislina Teva je zdravilo za redčenje krvi, ki vsebuje zdravilni učinkovini klopidogrel in acetilsalicilno kislino.
What is Clopidogrel/Acetylsalicylic acid Teva and what is it used for?
Kaj je zdravilo Klopidogrel/acetilsalicilna kislina Teva in za kaj se uporablja?
What benefits of Clopidogrel/Acetylsalicylic acid Teva have been shown in studies?
Kakšne koristi je zdravilo Klopidogrel/acetilsalicilna kislina Teva izkazalo v študijah?
Why is Clopidogrel/Acetylsalicylic acid Teva approved?
Zakaj je bilo zdravilo Klopidogrel/acetilsalicilna kislina Teva odobreno?
Clopidogrel/Acetylsalicylic acid Teva clopidogrel / acetylsalicylic acid
Klopidogrel/acetilsalicilna kislina Teva klopidogrel/acetilsalicilna kislina
Clopidogrel/Acetylsalicylic acid Teva can only be obtained with a prescription.
Izdaja zdravila Klopidogrel/acetilsalicilna kislina Teva je le na recept.
How does Clopidogrel/Acetylsalicylic acid Teva work?
Kako zdravilo Klopidogrel/acetilsalicilna kislina Teva deluje?
How is Clopidogrel/Acetylsalicylic acid Teva used?
Kako se zdravilo Klopidogrel/acetilsalicilna kislina Teva uporablja?
This is called overgrowth.
To se imenuje prekomerna rast.
if you are suffering from more than one infection.
Če trpite zaradi več kot ene okužbe.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 02 September 2011
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 2. september 2011
From a microbiological point of view the product should be used immediately.
Z mikrobiološkega stališča je treba zdravilo porabiti takoj.
A course of treatment usually lasts for 7 to 21 days.
Zdravljenje običajno traja od 7 do 21 dni.
The minimum inhibitory concentration (MIC) breakpoints are as follows:
Prekinitvene točke minimalne inhibitorne koncentracije (MIC) so naslednje:
Both effects were reversible following an 8 week recovery period.
Oba učinka sta bila odpravljiva po 8-tedenskem obdobju okrevanja.
Stopping or slowing the infusion may result in cessation of these reactions.
Zaustavitev ali upočasnitev infundiranja lahko ustavi te reakcije.
The potential risk for humans
Potencialno tveganje za
At least 10,000 Gram-positive isolates per year shall be included in the study from the surveillance networks in Europe, USA, Latin America and Asia-Pacific.
V študijo bo vključenih vsaj 10.000 grampozitivnih izolatov letno iz mrež namenskega spremljanja v Evropi, ZDA, Latinski Ameriki in Aziji s Tihim oceanom.
Intermediate analysis results should be provided starting May 2015.
Rezultate vmesne analize je treba zagotavljati od maja 2015 naprej.
Telavancin has a small volume of distribution.
Telavancin ima majhen volumen distribucije.
Final study results by 31 December
Končni rezultati študije do 31. decembra
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Razmisliti je treba o uradnih priporočilih glede ustrezne uporabe antibakterijskih učinkovin.
Alternatively, your doctor may decide that this medicine is not suitable for you.
Namesto tega se lahko vaš zdravnik odloči, da to zdravilo za vas ni primerno.
The Healthcare Professional Guide should contain the following key messages:
Priročnik za zdravstvene delavce mora vsebovati naslednja ključna sporočila:
The use of antibiotics may promote the overgrowth of non-susceptible micro-organisms.
Uporaba antibiotikov lahko spodbudi prekomerno rast neobčutljivih mikroorganizmov.
Preparation of the reconstituted concentrate
Priprava rekonstituiranega koncentrata
Tell your doctor that
Povejte zdravniku,
Tell your doctor if you are pregnant, think you may be pregnant, or are trying to become pregnant.
Povejte zdravniku, če ste noseči, sumite, da ste noseči ali poskušate zanositi.
if you are allergic to antibiotics such as vancomycin.
Če ste alergični na antibiotike, kot je vankomicin.
What you need to know before you use VIBATIV
Kaj morate vedeti, preden boste uporabili zdravilo VIBATIV
The first signs of a severe allergic reaction may include swelling of the skin, face and/or throat and/or difficulty breathing.
Prvi znaki hude alergijske reakcije so lahko otekanje kože, obraza in/ali grla in/ali težko dihanje.
The elimination half-life in subjects with normal renal function is approximately 8 hours.
Razpolovna doba izločanja pri osebah z običajno ledvično funkcijo je približno 8 ur.
Human plasma protein binding is approximately 90%, primarily to serum albumin.
Vezava na humane plazemske proteine je približno 90 %, predvsem na serumski albumin.
Your doctor will treat you as necessary.
Vaš zdravnik vas bo zdravil, kot je potrebno.
The frequency of adverse reactions is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Pogostost neželenih učinkov: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The AUC of the predominant metabolite accounted for approximately 2-3% of AUC of telavancin.
AUC prevladujočega metabolita je znašal približno 2-3 % AUC-ja telavancina.
Creatinine clearance* (ml/min)
Očistek kreatinina* (ml/min)
VIBATIV should be used only in situations where it is known or suspected that other alternatives are not suitable (see sections 4.3, 4.4, 4.8 and 5.1).
Zdravilo VIBATIV se lahko uporablja le v primerih, ko je znano oz. ko se sumi, da druge možnosti niso ustrezne (glejte poglavja 4.3, 4.4, 4.8 in 5.1).
As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.
Po potrebi je treba poiskati nasvet strokovnjaka, ko je lokalno prevladovanje odpornosti tolikšno, da je delovanje učinkovine vsaj pri nekaterih vrstah okužb vprašljivo.
VIBATIV can only be used when other antibiotics are not suitable.
Zdravilo VIBATIV lahko uporabljamo le, kadar drugi antibiotiki niso primerni.
Activated partial thromboplastin time
Aktiviran parcialni tromboplastinski čas
The potential risk for humans is unknown (see section 4.6).
Potencialno tveganje za človeka ni znano (glejte poglavje 4.6).
Detailed information on this medicine is available on the European Medicines Agency website:
Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila:
if you are suffering from heart disorders.
Če trpite zaradi okvar srca.
Infusion related reactions can be limited if the daily dose is infused over a 1 hour period.
Reakcije, povezane z infundiranjem, je mogoče omejiti, če je dnevni odmerek infundiran v času 1 ure.
if you notice a change in your hearing.
Če zaznate spremembo v sluhu.
In the absence of compatibility studies, this medicine must not be mixed with other medicines.
Zaradi pomanjkanja študij kompatibilnosti se to zdravilo ne sme mešati z drugimi zdravili.
Recommendations for dose adjustment can be found in section 4.2.
Priporočila glede prilagoditev odmerka se nahajajo v poglavju 4.2.
Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other
Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
Store in a refrigerator (2-8°C).
Shranjujte v hladilniku (2-8 °C).
• The existence and scope of the pregnancy register and details of how to enter patients into it.
• Obstoj in obseg registra nosečnosti ter podatki, kako vključiti bolnice vanj.
The final protocol for the PASS should be provided to the CHMP by 30 April 2014.
Končni protokol za študijo PASS mora biti predložen CHMP do 30. aprila 2014.
Read all of this leaflet carefully before you are given this medicine because it contains important
Preden prejmete to zdravilo, natančno preberite navodilo, ker vsebuje za vas pomembne
Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as
Ker se poročila o teh reakcijah poročajo prostovoljno in velikost te populacije ni znana, ne moremo realno oceniti njihove pogostnosti, zato smo jih razvrstili kot neznano.
Your doctor may decide to adjust the rate of the infusion.
Vaš zdravnik bo morda prilagodil hitrost infuzije.
Changes in AUC only become clinically relevant in patients with moderate and severe renal impairment.
Spremembe v AUC postanejo klinično pomembne le pri bolnikih z zmerno in hudo ledvično okvaro.
What VIBATIV is and what it is used for 2.
Kaj je zdravilo VIBATIV in za kaj ga uporabljamo 2.
It is only used when the bacteria that cause these infections can be killed with telavancin.
Uporablja se samo v primeru, ko je bakterije, ki so povzročile okužbo, možno uničiti s telavancinom.
If your kidneys do not work well or if you are overweight, the dose may be reduced.
Če vaše ledvice ne delujejo dobro ali če imate prekomerno telesno maso, je odmerek lahko znižan.
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections.
Prevladovanje pridobljene odpornosti lahko za izbrane vrste geografsko in sčasoma variira; zaželeni so lokalni podatki o odpornosti, še posebej pri zdravljenju hujših okužb.
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Zaradi pomanjkanja študij kompatibilnosti se to zdravilo ne sme mešati z drugimi zdravili, z izjemo zdravil, ki so navedena v poglavju 6.6.
The recommended dosage regimen is 10 mg/kg, once every 24 hours, for 7 to 21 days.
Priporočeni režim odmerjanja je 10 mg/kg, na vsakih 24 ur, 7 do 21 dni.
Not known: frequency cannot be estimated from the available data severe allergic reactions (anaphylaxis).
Neznano (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov) hude alergijske reakcije (anafilaksija).
Therefore, no dosage adjustment is necessary based on gender.
Prilagoditev odmerka glede na spol zato ni potrebna.
Final study results by 31 May 2017
Končni rezultati študije do 31. maja 2017
Higher concentrations were observed in alveolar macrophages with ratios varying between 0.360 (at 4 h) and 6.67 (at 24 h).
Višje koncentracije so bile opažene pri alveolarnih makrofagih z variirajočimi razmerji med 0,360 (po 4 urah) in 6,67 (po 24 urah).
Ringing in the ears and deafness are possible side effects.
Zvonjenje v ušesih in gluhost sta možna
While antibiotics including VIBATIV fight certain bacteria, other bacteria and fungi may continue to grow.
Medtem ko antibiotiki, vključno z zdravilom VIBATIV, uničujejo določene bakterije, lahko druge bakterije in glivice rastejo dalje.
The results shall be reported to the CHMP on an annual basis and the final report shall be submitted no later than 31 May 2017.
O rezultatih je treba letno poročati CHMP in končno poročilo je treba predložiti najpozneje do 31. maja 2017.
The use of VIBATIV is contraindicated during pregnancy (see section 4.3).
Uporaba zdravila VIBATIV je med nosečnostjo kontraindicirana (glejte poglavje 4.3).
Both studies consistently showed that the area under the curve (AUC) of telavancin, but not the maximum plasma concentration (Cmax) increases with decreasing renal function.
Obe študiji sta pokazali, da območje pod krivuljo (AUC) telavancina, ne pa tudi maksimalna koncentracija v plazmi (Cmax), narašča z upadanjem ledvične funkcije.
Final results of the study and the re-evaluation of the benefit/risk ratio for Vibativ should be provided to CHMP no later than 31 December 2017.
Končni rezultati študije in ponovna ocenitev razmerja med koristmi in tveganji za zdravilo Vibativ morajo biti predloženi CHMP najpozneje 31. decembra 2017.
Mean (SD) AUC0-24 amounts to 780 (125) µg.h/ml.
Povprečna (SD) AUC0-24 znaša 780 (125) µg.h/ml.
If this happens, the infusion of telavancin will be stopped and the doctor will check the functioning of your kidneys.
Če se to zgodi, bo potrebno prekiniti infuzije telavancina, zdravnik pa bo preveril delovanje vaših ledvic.
Analysis of patient population pharmacokinetic data did not show a relevant effect of age on pharmacokinetics.
Analiza farmakokinetičnih podatkov populacije bolnikov ni pokazala znatnega učinka starosti na farmakokinetiko.
Your doctor will monitor you for any potential infections and treat you if necessary.
Vaš zdravnik vas bo opazoval glede možnih okužb in vas po potrebi zdravil.
All-cause mortality was 32/73 (44%) in the telavancin group and 16/64 (25%) in the vancomycin group, whereas in patients without acute renal failure at baseline it was 118/678 (17%) and 124/688 (18%), respectively.
Skupna smrtnost je znašala 32/73 (44%) pri skupini z zdravilom telavancin in 16/64 (25%) pri skupini z vankomicinom, medtem ko je bila pri bolnikih brez akutne odpovedi ledvic v izhodišču 118/678 (17%) in 124/688 (18%).
Despite in vitro susceptibility, there are insufficient clinical data to assess the potential for efficacy of telavancin in infections due to hGISA/GISA.
Kljub občutljivosti in vitro klinični podatki niso zadostni za ocenitev potenciala za učinkovitost telavancina pri okužbah zaradi hGISA/GISA.
Systemic macrophage hypertrophy and hyperplasia occurred in rats and dogs, in many organ systems that normally contain macrophages.
Hipertrofija in hiperplazija sistemskih makrofagov se je pri podganah in psih pojavila v številnih organskih sistemih, ki običajno vsebujejo makrofage.
Treatment was discontinued due to adverse reactions in 5.0% of patients who received telavancin.
Zdravljenje je bilo prekinjeno zaradi neželenih učinkov pri 5,0 % oseb, ko so prejemale telavancin.
Foaming may occur during reconstitution but will dissipate upon standing.
Med rekonstitucijo se lahko pojavi penjenje, vendar se bo po mirovanju razpršilo.
Do not take any diarrhoea medicine without first checking with your doctor.
Ne vzemite zdravil proti driski, ne da bi se prej posvetovali s svojim zdravnikom.
S. aureus (including methicillin-resistant strains)
S. aureus (vključno s proti meticilinu odpornim sevom)
If superinfection occurs during therapy, appropriate measures should be taken.
Če se superokužba pojavi med zdravljenjem, je treba uvesti ustrezne ukrepe.
The Marketing Authorisation Holder shall agree the format and content of the Healthcare Professional Guide with the National Competent Authority in the Member State.
Imetnik dovoljenja za promet z zdravilom se dogovori o obliki in vsebini Priročnika za zdravstvene delavce s pristojnim nacionalnim organom v državi članici.
The safety and efficacy of VIBATIV in children and adolescents aged below 18 years have not yet been established.
Varnost in učinkovitost zdravila VIBATIV pri otrocih, mlajših od 18 let, še nista bili dokazani.
• The Healthcare Professional Guide
• Priročnik za zdravstvene delavce.
Like all medicines, VIBATIV can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo VIBATIV neželene učinke, ki pa se ne pojavijo pri vseh
The liver, kidney, macrophages and testis were identified as target organs of toxicity in animals.
Jetra, ledvice, makrofagi in moda so bili identificirani kot ciljni organi zastrupitve pri živalih.
For storage conditions of the reconstituted or diluted medicinal product, see section 6.3.
Za pogoje shranjevanja rekonstituiranega ali razredčenega zdravila glejte poglavje 6.3.
In combination with the small Vss, this results in a t1/2 of about 8 h.
V kombinaciji z majhnim Vss se to kaže v razpolovnem času (t1/2) približno 8 ur.
In a mass balance study in male subjects using radiolabeled telavancin, 3 hydroxylated metabolites were identified with the predominant metabolite (THRX-651540) accounting for <10% of the radioactivity in urine and <2% of the radioactivity in plasma.
V študiji masnega ravnotežja na moških z uporabo radioaktivno označenega telavancina, so bili s prevladujočim metabolitom (THRX-651540) identificirani 3 hidroksilni metaboliti, kar je znašalo <10 % radioaktivnosti v urinu in <2 % radioaktivnosti v plazmi.
Although telavancin does not interfere with coagulation, it interfered with certain tests used to monitor coagulation (see below), when tests are conducted using samples drawn between 0 to 18 hours after telavancin administration to patients being treated once every 24 hours.
Čeprav telavancin ne ovira koagulacije, je oviral določene teste, ki se uporabljajo za nadzorovanje koagulacije (glejte spodaj), ko se testi izvajajo s pomočjo vzorcev, vzetih med 0 in 18 ur po dajanju telavancina bolnikom, ki prejmejo odmerek vsakih 24 ur.
In vitro experiments indicate that telavancin will not affect the clearance of medicinal products metabolised by CYP isoforms 1A2, 2C9, 2C19 and 2D6.
In vitro poskusi kažejo, da telavancin ne bo vplival na očistek zdravil, ki jih presnavljajo izoforme CYP 1A2, 2C9, 2C19 in 2D6.
• Healthcare professionals should be aware that the administration of Vibativ may interfere with some coagulation laboratory tests and qualitative and quantitative urine protein tests.
• Zdravstveni delavci se morajo zavedati, da lahko uporaba zdravila Vibativ vpliva na nekatere teste koagulacije ter kakovostne in količinske analize beljakovin v urinu.
Vibativ should be used with caution with other nephrotoxic medicinal products.
Zdravilo Vibativ je treba uporabljati previdno, če uporabljate druga nefrotoksična zdravila.
Since telavancin is primarily excreted unchanged by renal clearance and multiple CYP enzymes are able to metabolise telavancin, no relevant interactions are expected with inhibitors or inducers of the CYP450 system.
Ker se telavancin izloča predvsem nespremenjen z ledvičnim očistkom in več encimov CYP lahko presnavlja telavancin, ni pričakovati pomembnih interakcij z inhibitorji ali induktorji sistema CYP450.
Telavancin is mainly excreted unchanged accounting for approximately 82% of the total amount recovered over 48 hours in urine.
Telavancin se v glavnem izloča nespremenjen v približno 82 % od celokupne količine, ki se v 48 urah izloči z urinom.